Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...
Zacks.com on MSN7h
AMGN Stock Down Despite Strong Data From Obesity Drug StudyKey Takeaways A new Amgen weight reduction drug, MariTide, has bred successful results after a 52-week study. Still, AMGN ...
A new HHS rule would require Medicare and Medicaid to cover drugs like Wegovy or Zepbound for a large segment of Americans.
8h
The CMS estimated that coverage of the weight-loss drugs will cost the federal government about $25 billion for Medicare and ...
New research from the University of Mississippi (UM) indicated that some sugar may benefit you when taking certain ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.
Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.
With expected sales for GLP1Rs in obesity estimated to surpass $126 billion by 2030, this drug category presents a lucrative ...
The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid.
A new Biden administration proposal could allow millions of Americans with obesity to access weight-loss drugs like Wegovy ...
The Biden administration announced Tuesday it’s reinterpreting federal law to allow Medicare and Medicaid patients access to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback